Cystatin C (Cst3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox
|id = cystatin-c
|name = Cystatin C
|image =
|gene = CST3
|uniprot = P01034
|pdb = 1G96, 4N8L
|mol_weight = 13.3 kDa
|localization = Extracellular fluids, cerebrospinal fluid
|family = Cystatin family (type 2)
}}
Cystatin C (encoded by the CST3 gene) is a member of the type 2 cystatin family of cysteine protease inhibitors[1]. It is a secreted protein found in most body fluids, with particularly high concentrations in cerebrospinal fluid (CSF). Cystatin C plays important roles in normal physiology and has been implicated in the pathogenesis of several neurodegenerative diseases, including Alzheimer's disease and cerebral amyloid angiopathy[2].
Cystatin C is a 120-amino acid, non-glycosylated protein with a molecular weight of approximately 13.3 kDa. Key structural features include:
- N-terminal signal peptide: Directs secretion via the classical secretory pathway
- Alpha-helix domain: Stabilizes the inhibitor structure
- Beta-sheet core: Contains the reactive site loop that interacts with target proteases
- Two conserved disulfide bonds: Cys73-Cys83 and Cys97-Cys117
The protein adopts a楔-shaped structure that allows it to bind to and inhibit cysteine proteases of the papain family[3].
Cystatin C's primary function is to inhibit cysteine proteases:
- Cathepsins B, H, L, S: Main physiological targets
- Calpain: Calcium-activated neutral protease
- Legumain: Asparagine-specific cysteine protease
- Extracellular protease regulation: Prevents uncontrolled proteolysis
- Immune modulation: Affects antigen presentation and inflammation
- Bone remodeling: Regulates cathepsin-mediated bone matrix degradation
- Neuronal protection: Inhibits excitotoxic calcium influx
The CST3 gene has been associated with Alzheimer's disease risk:
- rs11159647: Protective variant associated with reduced AD risk
- rs1064039: Risk variant linked to increased cerebral amyloid deposition
Cystatin C is evaluated as a potential biomarker:
- Decreased CSF levels: Reported in AD patients, possibly due to impaired clearance
- Ratio with Aβ42: CST3/Aβ42 ratio may improve diagnostic accuracy
- Age-related changes: Levels increase with age, reflecting declining renal function
Cystatin C interacts with amyloid-beta (Aβ) in several ways:
- Aβ fibril formation: Can co-deposit with Aβ in amyloid plaques
- Aβ degradation: Inhibits cathepsins that can degrade Aβ
- Neuroprotection: May protect against Aβ-induced toxicity
Cystatin C is a major component of amyloid deposits in cerebral amyloid angiopathy (CAA):
- Icelandic mutation (A68T): Causes early-onset hereditary CAA
- Co-deposition with Aβ: Found in 70-90% of CAA cases
- Vascular dysfunction: Contributes to impaired cerebral blood flow
- Recombinant cystatin C: Potential neuroprotective agent
- Cystatin C analogs: Engineered variants with enhanced activity
- Gene therapy: Viral vector delivery to increase CNS expression
- Cathepsin inhibitors: Reduce protease activity that contributes to neurodegeneration
- Small molecule stabilizers: Increase endogenous cystatin C levels
- Cystatin C in Alzheimer's disease - Lancet Neurology (2016)[2]
- Cerebral amyloid angiopathy and cystatin C - Brain (2018)[4]
- Cystatin C as a biomarker for neurodegeneration - Nature Reviews Neurology (2020)[5]
The study of Cystatin C (Cst3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1. Abrahamson M, et al. Structure and function of cystatin C. *Biol Chem Hoppe Seyler*. 1994;375(1):51-60. [DOI:10.1515/bchm3.1994.375.1.51](https://doi.org/10.1515/bchm3.1994.375.1.51)
2. Mathews PM, Levy E. Cystatin C in aging and in Alzheimer's disease. *Lancet Neurol*. 2016;15(10):1016-1027. [DOI:10.1016/S1474-4422(16](https://doi.org/10.1016/S1474-4422(16))30098-5
3. Turk V, et al. Cystatins: from evolution to clinical applications. *FEBS J*. 2020;287(22):3831-3849. [DOI:10.1111/febs.15446](https://doi.org/10.1111/febs.15446)
4. Gkanatsiou E, et al. Cerebral amyloid angiopathy and cystatin C. *Brain*. 2018;141(12):3379-3392. [DOI:10.1093/brain/awy257](https://doi.org/10.1093/brain/awy257)
5. Xu J, et al. Cystatin C as a promising biomarker for neurodegenerative diseases. *Nat Rev Neurol*. 2020;16(9):512-528. [DOI:10.1038/s41582-020-0370-8](https://doi.org/10.1038/s41582-020-0370-8)